EMJ Cardiology 9 [Supplement 1] . 2021

In this issue

At this year’s American Heart Association (AHA) Scientific Sessions, the latest insights from clinical studies were shared to inform high-quality care by cardiologists worldwide. Dr Sheila Hegde and Dr Sara Saberi presented findings from the EXPLORER-HCM Study into the benefits of mavacamten, a first-in-class selective cardiac myosin inhibitor, on the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (HCM). Insights from these poster presentations were outlined in this article.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.